Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer (Q35095635)

6 August 2017

1 reference

title

Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer (English)

1 reference

6 August 2017

Cornelia Liedtke

1

1 reference

6 August 2017

Ludwig Kiesel

series ordinal

2

1 reference

6 August 2017

publication date

27 May 2011

1 reference

6 August 2017

1 reference

6 August 2017

volume

6

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

234-239

1 reference

Triple-negative breast cancer: disease entity or title of convenience?

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Triple-negative breast cancer--current status and future directions

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

BRCA1 dysfunction in sporadic basal-like breast cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Hallmarks of 'BRCAness' in sporadic cancers

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

9 July 2018

1 reference

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

21 January 2018

1 reference

Migraine history and breast cancer risk among postmenopausal women

21 January 2018

1 reference

Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation

21 January 2018

1 reference

Histopathological criteria and selection algorithms for BRCA1 genetic testing.

21 January 2018

1 reference

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

21 January 2018

1 reference

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3132973

27 September 2018

Identifiers

DOI

10.1159/000328964

1 reference

6 August 2017

1 reference

6 August 2017

1 reference